Acarbose as effective as metformin in curbing HbA1C, study finds

10/28/2013 | MedPage Today (free registration)

Data on patients newly diagnosed with type 2 diabetes revealed those who took acarbose attained a mean HbA1C reduction of 1.11% at 48 weeks, while those in the metformin arm had a 1.12% decline during the same period. Metformin should still be the primary treatment for patients, although an alpha-glucosidase inhibitor can be used as an alternative treatment before acarbose's heart benefits are validated in further studies, researchers wrote in The Lancet Diabetes & Endocrinology.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Medical Director - Physician
Willamette Valley Community Health
Salem, OR